Tebotelimab (MGD-013) is a bispecific antibody targeting PD-1 and LAG-3, classified as a human IgG4κ dual-affinity re-targeting (DART) molecule. It exhibits binding affinities with EC50 values of 1.65 nM for PD-1 and 0.41 nM for LAG-3 on NS0 cells. The compound effectively inhibits PD-1/PD-L1, PD-1/PD-L2, and LAG-3/HLA (MHC-II) interactions, alongside PD-1 signaling pathways. By doing so, Tebotelimab reinvigorates exhausted T-cell responses and bolsters antitumor immunity [1] [2] [3].